Global Anti-Fungal Treatment Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines), By Indication (Systemics, Candidiasis, Cryptococcosis, Prophylactic Use of Antifungals, Coccidioidomycosis), By Pathogen (Candid, Aspergillus, Cryptococcus, CoccidiodiesImmitis, Zygomycetes, Trichophytons), By End-User (Hospitals & Clinics, Dermatology, Clinics), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Fungi are microorganisms that can subsist in a wide range of environments and cause a variety of ailments in people, from superficial skin infections to systemic infections that infect individuals through inhalation. These infections develop in the human body as a result of prolonged contact with fungus-infested environments or impaired immune systems. A number of antifungal drugs such as echinocandins, azoles, etc., are utilized for its treatment.

Detailed Segmentation –

The global anti-fungal treatment market is segmented on the basis of – Drug Class, Indications, Pathogens, End-Users, and Region. Represented below is a detailed segmental description:

Based on Drug Class:

• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Pyrimidines

Based on Indication:

• Systemics
• Candidiasis
• Cryptococcosis
• Prophylactic Use of Antifungals
• Coccidioidomycosis

Based on Pathogen:

• Candid
• Aspergillus
• Cryptococcus
• CoccidiodiesImmitis
• Zygomycetes
• Trichophytons

Based on End-User:

• Hospitals & Clinics
• Dermatology
• Clinics

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Anti-Fungal Treatment Market:

Fungal infections are mainly found in people who have a weak immune system or have immunological issues. They were also the leading cause of death among children and teenagers. For instance, approximately 220,000 cases of cryptococcal meningitis are reported each year in AIDS patients across the world. Antifungal drugs come in a wide range of delivery systems, which may in turn help to boost the revenue growth of this market.

Opportunity for the Global Anti-Fungal Treatment Market:

The development of new drugs can provide extensive revenue growth opportunities for this market.

Restraints for the Global Anti-Fungal Treatment Market:

In contrast to its curative advantages, antifungal medication can have a number of side-effects such as anemia, itching, irritation, headaches, diarrhea, etc. It is also to blame for kidney and liver damage. Moreover, a number of antifungal drugs have the potential to cause allergic reactions. These effects can restraint the economic trajectory of this market.

Competitive Landscape –

Key players in this market are –

• Pfizer Inc.
• Astellas Pharma Ltd.
• Novartis International AG
• Sanofi S.A.
• Merck KGaA
• Bayer AG
• Abbott Laboratories
• Janssen Pharmaceuticals
• Gilead Sciences Inc.
• Cipla Inc.
• others

These key industry players are now focusing on mergers, partnerships, acquisitions, product developments, and collaboration strategies, in order to sustain their respective competitive edges.

Key Developments-

Year 2020

• Sanofi (France) renewed a five-year deal worth USD 25 million with the WHO to combat Neglected Tropical Diseases (NTD) in December 2020. NTDs are a set of parasitic, bacterial, fungal, and viral disorders that affect or endanger approximately one billion people around the world.
• With a new USD 59 million production unit in the Beijing Economic-Technological Development Area, Bayer (Germany) projected a 40% increase in output at the Beijing production site in August 2020.

For the Anti-Fungal Treatment Market research study, the following years have been considered to estimate the market size: